Alamar NULISA
Our proteomic services span the full sensitivity range of immuno-affinity protein quantification, now including NULISA technology for ultra-sensitive attomolar detection of low-abundance proteins. By leveraging dual amplification for superior background reduction, this assay provides ~10,000x greater sensitivity than standard immunoassays while requiring minimal sample volume. Enhance your neurology, immunology, and oncology research with our validated workflows as a Certified Service Provider of Alamar’s NULISA proteomics platform.
For unrivaled protein analysis, pair Alamar with Olink® for seamless integration into your multiomics workflow.
Is GENEWIZ an Alamar NULISA Certified Services Provider?
As a Certified Service Provider (CSP) of Alamar NULISA technology, we offer uniquely scalable solutions from Neuro 220 to Inflammation 250, as well as Oncology and Autoimmune targeted panels for tumor, autoantibody, and low-abundance targeting.
Should I choose olink or nulisa?
While both Olink and NULISA utilize dual antibody barcoding, the targets vary substantially between platform. Which assay you choose will depend on the goal of your study and your key targets of interest. Learn more about how these two platforms compare and which to use for your specific application.
NULISA Proteomics Panels
NULISA platforms deliver ultra-sensitive targeted proteomics with disease-focused panels for neuroscience, inflammation, oncology, and autoimmune research.
| NULISA Platform | Description | Details | Download |
|---|---|---|---|
| NULISAseq Neuro 220 Panel | With comprehensive coverage of the hallmarks of neurological disease, the NULISAseq Neuro 220 Panel offers unprecedented insight into the biological mechanisms involved in Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Amyotrophic lateral sclerosis, Multiple Sclerosis and Gliomas. |
|
Click to download the assay list: NULISAseq Neuro 220 Panel |
| NULISAseq CNS Disease Panel 120 | The NULISASeq CNS Disease Panel 120 enables ultra-sensitive, multiplexed quantification of 120+ neuro-specific and inflammatory proteins |
|
Click to download the assay list: NULISAseq CNS Disease Panel 120 |
| NULISAseq Inflammation Panel 250 | NULISAseq Inflammation Panel 250 provides the most comprehensive coverage of immune response with unprecedented sensitivity to detect baseline levels of low abundant cytokines. |
Reliably discover and validate inflammatory biomarkers across diverse disease states:
|
Click to download the assay list: NULISAseq Inflammation Panel 250 |
| NULISAseq Inflammation Panel AQ | Compare the relative quantities for over 250 proteins while generating absolute quantitative values for >150 biomarkers with the NULISAseq Inflammation Panel AQ. |
Discover novel signatures across 250 targets while delivering precise absolute quantitative measurements for over 150 key biomarkers, including:
|
Click to download the assay list: NULISAseq Inflammation Panel AQ |
| NULISAseq Mouse Panel 250 | Encompassing 120 proteins selected for their importance in biomedical research, the NULISAseq Mouse Panel 120 targets key pathways involved in inflammation, neurodegeneration and oncogenesis. |
|
Click to download the assay list: NULISAseq Mouse Panel 250 |
| NULISAqpcr Assays | For high sensitivity measurement of validated biomarkers |
Options include:
|
Applications of Proteomics
-
Neurodegenerative cohort profiling in plasma and CSF
-
Cytokine and IFN signature work in autoimmune and inflammation studies
-
Companion proteomics layered onto bulk RNA-Seq, single cell, or methylation data
-
Low input or precious sample studies where volume is limiting
-
Translational biomarker discovery and verification across phases
The GENEWIZ Difference
-
Certified Service Provider of Alamar proteomics technology
-
Supplemental genomic, transcriptomic, and epigenomic analysis available
-
Wide variety of sample types accepted
-
Clinical sample handling, transportation, and processing available for RUO or in our GCP-compliant CLIA and CAP laboratory for clinical applications
-
Flexible turnaround times tailored to meet your project deadlines, whether you need expedited results or a more relaxed timeline
Technical Resources
-
Webinar │ Beyond the Genome: Revolutionizing Health with Population-Scale Proteomics and Biomarker Discovery
In this webinar, co-hosted with Olink, discover the role of proteomics in advancing personalized medicine. Our guest speaker, Haythem Latif, Ph.D., provides insights on the importance of biomarkers and how you can effectively integrate proteome data with large-scale genomic datasets to broaden your understanding of human health. Plus, learn about recent population-scale studies utilizing protein biomarker discovery to go beyond the genome.
-
Blog | Comparing Mass Spectrometry, ELISA, and Olink for Proteomics
The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics – mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) – and highlight their strengths and limitations.
-
Blog │ The Power of Proteomics
The landscape of drug development is constantly evolving, fueled by groundbreaking scientific advancements. While genetics has played a central role in understanding diseases, proteomics provides a more comprehensive picture of disease phenotypes and mechanisms. In this blog, discover how researchers and clinicians are using Olink proteomics to reshape the outcomes of their clinical studies.
-
Blog | Olink vs NULISA: Which Should I Choose?
The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics – mass spectrometry, ELISA, and the Olink Proximity Extension Assay (PEA) – and highlight their strengths and limitations.
-
Webinar | Precision Proteomics: How to Enable Biomarker Identification in Health and Disease
Hear directly from Olink Proteomics about precision protein analysis as a tool to improve health outcomes for patients with cancer, inflammatory, or age-related diseases. Take this chance to discover how you can bring your protein biomarker discovery to the next level with Olink PEA technology.
NGS Platforms
For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. GENEWIZ does not guarantee data output or quality for sequencing-only projects.
